EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature

Shin-Ichiro Ohmura iD, Yoichiro Homma, Shiho Hanai, Yoshiro Otsuki, Toshiaki Miyamoto

Modern Rheumatology Case Reports · 2023

DOI: 10.1093/mrcr/rxac023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Modern Rheumatology Case Reports, 2023. Verfasst von Shin-Ichiro Ohmura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan. Hauptthemen laut MEDLINE: Pyoderma Gangrenosum, Arthritis, Rheumatoid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyoderma gangrenosum (PG) is a rare chronic skin disease characterised by painful skin ulcers. There are no treatment guidelines for PG, but systemic treatments including biologics are often used. Recently, adalimumab (ADA), a fully human monoclonal antibody against tumour necrosis factor, was approved for refractory PG treatment in Japan. Herein, we report a case of rheumatoid arthritis with refractory PG 2 months after orthopaedic surgery of the foot during treatment with low-dose etanercept and methotrexate. Although adding a moderate dose of glucocorticoid did not improve her PG, the patient showed a remarkable response after switching from etanercept to ADA in a higher dose than that used to treat rheumatoid arthritis. This higher dose of ADA may be effective for the treatment of refractory PG after the failure of other tumour necrosis factor inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pyoderma GangrenosumArthritis, RheumatoidFemaleHumansAdalimumabEtanerceptTumor Necrosis Factor InhibitorsInfliximabAntibodies, Monoclonal, HumanizedReceptors, Tumor Necrosis FactorImmunoglobulin G

Stichwörter der Autor:innen

Pyoderma gangrenosumadalimumabetanerceptrheumatoid arthritistumour necrosis factor inhibitors

Substanzen

AdalimumabEtanerceptTumor Necrosis Factor InhibitorsInfliximabAntibodies, Monoclonal, HumanizedReceptors, Tumor Necrosis FactorImmunoglobulin G

Autor:innen und Institutionen

  • Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of General Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of Dermatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of Pathology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.

ORCID-Profile: Shin-Ichiro Ohmura

Zitieren

APA

Ohmura, S. I., Homma, Y., Hanai, S., Otsuki, Y., & Miyamoto, T. (2023). Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxac023

Vancouver

Ohmura SI, Homma Y, Hanai S, Otsuki Y, Miyamoto T. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature. Modern Rheumatology Case Reports. 2023. doi:10.1093/mrcr/rxac023

BibTeX
@article{Ohmura2023,
  author = {Ohmura, Shin-Ichiro and Homma, Yoichiro and Hanai, Shiho and Otsuki, Yoshiro and Miyamoto, Toshiaki},
  title = {Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  doi = {10.1093/mrcr/rxac023}
}
Kostenlos starten →